Company insider dossier

X4 Pharmaceuticals Inc insider intelligence

XFOR filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.

Terminal chart Weekly report Factor intelligence Healthcare Biotechnology Data API
25/100

Concentrated distribution

37/100 confidence
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Latest evidence
1 Jul 2026

Investment committee read

Concentrated distribution

Priced common-share disposals are concentrated enough to warrant review, but they are not treated as a standalone bearish forecast.

Review exposure and filing context

Evidence in favour

  • The evidence is retained for monitoring, but no broad conviction cluster is present yet.

Decision risks

  • Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.
  • The latest qualifying filing is more than 30 days old.
Conviction25Concentrated distribution
Confidence37Thin evidence
Named insiders2participating in the tape
Controlled events2directional common-share events
Acquisition value$0normalized amount
Disposal value$109.2Knormalized amount

Price confirmation map

Weekly price with common-share events

Acquisitions and disposals are aligned to the nearest completed weekly bar.

15.2611.808.344.891.43 Disposal · 30 Jun 2026 · $36.4KDisposal · 12 May 2026 · $72.8K
Feb 2025Aug 2026
Weekly closeCommon-share acquisitionCommon-share disposal

Market confirmation

Price and trend context

Latest close
4.64 USD
One-week move
+16.6%
Four-week move
+5.2%
Fair-value gap
-68.2%
Trend signal
Active
Relative strength
6.3

Directional balance

Controlled event mix

0.0%acquisition
Acquisition events
0
Disposal events
2
Net value
-$109.2K

Cadence

Twelve-week filing pressure

Volume shows attention. Controlled events determine direction.

025 May
001 Jun
008 Jun
015 Jun
022 Jun
229 Jun
006 Jul
013 Jul
020 Jul
027 Jul
003 Aug
010 Aug

Named participants

Insider conviction by person

GOLD, KELLYDirector500 events
KIRSKE, DAVIDChief Financial Officer252 events

Evidence quality

Security and transaction context

Common equity2
Equity compensation0
Options and derivatives1
Other securities0

Role architecture

Who is participating

Finance leadership2
Director1

Transaction evidence

Auditable XFOR filing ledger

Showing 1 to 3 of 3.

GOLD, KELLYDirector
AcquisitionOptions and derivatives
110000 sharesStock Option (right to buy)
Not reportedContext evidence
KIRSKE, DAVIDChief Financial Officer
DisposalCommon equity
8543 sharesCommon Stock
$36.4KDirectional evidence
KIRSKE, DAVIDChief Financial Officer
DisposalCommon equity
16961 sharesCommon Stock
$72.8KDirectional evidence

Reading the dossier

Direction and confidence are separate

Conviction

The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.

Confidence

Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.

Disposals

Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.

Price confirmation

The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.

Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.

Evidence context